相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Current systemic therapy for metastatic melanoma
Sanjiv S. Agarwala
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma
Agop Y. Bedikian et al.
CANCER INVESTIGATION (2008)
Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
Lawrence Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) - A novel strategy for the treatment of melanoma and other malignancies
Steven J. O'Day et al.
CANCER (2007)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
AV Maker et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells
N van Baren et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma
WHJ Kruit et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
